Loading company…
NeuVasQ Biotechnologies develops therapies targeting blood-brain barrier function.
NeuVasQ develops pharmaceuticals intended to restore blood-brain barrier function in neurological disorders. Its work addresses conditions including stroke, epilepsy and Alzheimer’s. Founded in 2021 as a spin-off of the Université Libre de Bruxelles (ULB) and Prof. Benoit Vanhollebeke, it is based in Charleroi, Belgium, and raised EUR 20 million in Series A funding in June 2021.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in